Heinz A. Horst

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

Max S. Topp, Nicola Gökbuget, Anthony S. Stein et al. · The Lancet Oncology · 2014 · 1.3K citations

Medicine, Hematology, Oncology +13

Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial)

Oliver A. Cornely, Johan Maertens, Mark Bresnik et al. · Clinical Infectious Diseases · 2007 · 744 citations · Full text

Medicine, Infectious Diseases, Pharmacology +17

The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML

Sabine Käyser, Konstanze Döhner, Jürgen Krauter et al. · Blood · 2010 · 485 citations

Medicine, Hematology, Oncology +11

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

Max S. Topp, Nicola Gökbuget, Gerhard Zugmaier et al. · Blood · 2012 · 469 citations · Full text

Medicine, Hematology, Oncology +15

<i>RUNX1</i>Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group

Verena I. Gaidzik, Lars Bullinger, Richard F. Schlenk et al. · Journal of Clinical Oncology · 2011 · 450 citations · Full text

Life Sciences, Genetics, Molecular Genetics +16